BioSpace News Archive

Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech company.

The global oncology nutrition market size is expected to reach USD 3.92 Billion in 2030 and register a revenue CAGR of 8.6% over the forecast period, according to the latest report by Reports and Data.

Advancements in the healthcare sector have introduced modern medical devices that have revolutionized medical treatments, which improved the quality of life of people suffering from lifestyle and chronic diseases

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split, effective as of 5:00 p.m. Eastern Time today.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced the presentation of imaging data from the “cold antibody sub-study” evaluating pre-administration of cold antibody (naked antibody without the isotope) prior to administration of the imaging agent (antibody with the isotope) in the Phase 1 study of FPI-1434 for the treatment of solid tumors expressing IGF-1R.

I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based GMP cell manufacturing CDMO and personal iPSC banking provider, announced that the company has succeeded in developing a propriety automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously.

Sparrow Pharmaceuticals Presents Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the Endocrine Society (ENDO) 2022 Annual Meeting.

J INTS BIO announced that it will be presenting the preclinical results of its NSCLC candidate ‘JIN-A02' at the upcoming 2022 IASLC World Conference on Lung Cancer, to be held in Vienna, Austria from 6th to 9th August.

The global animal model market size is expected to reach USD 2.63 Billion in 2030 and register a revenue CAGR of 6.2% over the forecast period, according to latest report by Reports and Data.

Attralus, Inc today announced encouraging new clinical data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of AT-01 (Iodine I-124 evuzamitide), the company’s pan-amyloid binding peptide in development as a radiotracer for the diagnosis of multiple types of systemic amyloidosis.